The HemoScreen blood test analyzer device developed by PixCell Medical (Courtesy)
PixCell Medical, an Israeli maker of blood test analyzers, said Monday that South Korea’s Soulbrain Holdings has acquired all of the controlling shares of the company and has invested in the firm. This makes Soulbrain the majority shareholder of PixCell Medical. Financial details of the deal were not disclosed.
The acquisition is in line with the South Korean firm’s bid to transition from manufacturing semiconductors to the healthcare and in-vitro diagnostics space to boost growth, PixCell said in a statement. Soulbrain’s shares are traded on the Korean Securities Dealers Automated Quotations (KOSDAQ) exchange at a valuation of about $1 billion.
PixCell Medical Partners with Axonlab to Distribute Point-of-Care Hematological Analyzer HemoScreen Across Europe
YOKNEAM ILIT, Israel, April 21, 2021 /PRNewswire/ PixCell Medical, innovator of rapid diagnostic solutions at the point-of-care, today announced an exclusive distribution agreement with Axonlab, a leader in point-of-care testing in Europe providing the healthcare sector with equipment and services in the fields of medical diagnostics, life science, and software solutions, to distribute the HemoScreen, PixCell s hematology analyzer, in key European geographies.
Axonlab will have exclusive distribution rights in Switzerland, Austria, the Netherlands and the Czech Republic. Collaborating with reputable international supply partners to provide innovative diagnostic systems to clinics, doctors and the research sector is central to our identity as a company. We focus on delivering comprehensive, future-oriented services, and believe that PixCell s HemoScreen is an importa
RURAL Cohort Study to Utilize PixCell Medical s HemoScreen™ Hematology Analyzer for Research Initiative
USA - English
News provided by
Share this article
Share this article
YOKNEAM ILIT, Israel, Feb. 23, 2021 /PRNewswire/ PixCell Medical, innovator of rapid diagnostic solutions at the point-of-care, announced today that the Risk Underlying Rural Areas Longitudinal Study (RURAL) has selected PixCell s novel miniaturized, portable hematology analyzer, HemoScreen™, as part of its six year research study, aiming to gain insight into the specific health-related concerns of the rural southeastern United States population. The RURAL Study is funded by the National Heart, Lung and Blood Institute (NHLBI).
Led by a group of researchers from 16 different US institutions, the RURAL study aims to understand health concerns specific to rural communities in the South, particularly related to increased rates of heart, lung, blood and sleep disorders. Focusing on ten rural counties in
Aidian appointed sole distributor of PixCell Medicalâs HemoScreen in Nordic/Baltic Countries
3 February 2021
Shutterstock
Aidian appointed sole distributor of PixCell Medicalâs HemoScreen in Nordic/Baltic Countries
Highly detailed planet Earth in the morning. Exaggerated precise relief lit morning sun. Detailed Earth. Europe. Scandinavia. Elements of this image furnished by NASA
Aidian will serve as the sole distributor of PixCellâs HemoScreen, a hematology analyzer designed for use at the point of care, with exclusive distribution rights in Finland, Norway, Denmark, Latvia and Estonia.
Saila Pesonen, VP Business Development at Aidian, said: âOffering cost-effective and smart solutions for primary care is our central mission, and we are always looking for well-established diagnostic manufacturers developing innovative products to help us achieve this goal. In the Nordics, CRP tests are used in daily practice alongside hematological analysis, making
Search jobs PixCell Medical Partners with Triolab to Distribute Hematological Analyzer HemoScreen™ in Sweden
YOKNEAM ILIT, Israel – January 11, 2021 - PixCell Medical, innovator of rapid diagnostic solutions at the point-of-care, today announced a partnership with Triolab, the largest diagnostics distributor in the Nordic and Baltic countries, to be the sole distributor in Sweden of the HemoScreen™, PixCell’s hematology analyzer designed for use at the point of care.
“PixCell’s HemoScreen brings lab-quality hematology results closer to the patient, making it possible to analyze Complete Blood Count (CBC) with the five-part differential at a patient’s bedside, without the skills of a biomedical scientist, which is a prerequisite for traditional hematology,” said Johan Snis, Sales Manager of Triolab. “We have already seen evidence on how this can increase patient safety, enhance the patient experience by shortening the time spent in accide